AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21401801
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (3‐monthly spirometry with medical review)
Trial: 19824278
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl (TF)
Trial: 18060626
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy + atorvastatin (10 mg/day)
Trial: 15544079
Drug: Sliding screw
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sliding screw device combined with calcium‐phosphate cement for augmentation
Trial: 11227321
Drug: Psychodynamic oriented
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic oriented psychotherapy in addition to standardized medical treatment
Trial: 11227321
Drug: Standardized medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized medical treatment (Control group)
Trial: 7920211
Drug: Beta-carotene (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (30 mg/day) and vitamin A (25,000 international units/day)
Trial: 31150601
Drug: US-guided standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided standard subacromial injection
Trial: 31150601
Drug: Dual-target injection
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-target injection (subacromial bursa plus proximal biceps long-head tendon)
Trial: 24919604
Drug: Wheat fibre
RxNorm normalized name: triticum (wheat fibre)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat fibre (15 g day⁻¹)
Trial: 24919604
Drug: Inulin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (15 g day⁻¹)
Trial: 24919604
Drug: Control (refined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (refined grain, 15 g day⁻¹)
Trial: 15362934
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g daily of 95% ethyl esters of eicosapentaenoic acid (EPA)
Trial: 10631623
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and Paroxetine (comparison)
Trial: 10631623
Drug: Sertraline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline and Venlafaxine (comparison)
Trial: 10631623
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and Venlafaxine
Trial: 8725855
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (1.2 pmol . kg-1 . min-1)
Trial: 3881104
Drug: Diltiazem 180
RxNorm normalized name: diltiazem 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 180 mg/day and Propranolol 240 mg/day combined
Trial: 29985236
Drug: Critical Administration
RxNorm normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Critical Administration Threshold (CAT+), defined as 3 U or greater RBC in the first hour
Trial: 24915543
Drug: Low-dose fish
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fish oil (2.4 g/day)
Trial: 24915543
Drug: High-dose fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fish oil (16.2 g/day)
Trial: 24382614
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 100% lavender oil (3 mL in a glass jar at bedside from 10 pm to 6 am)
Trial: 24382614
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 100% lavender oil
Trial: 22239862
Drug: Flibanserin 100
RxNorm normalized name: flibanserin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 100 mg once daily
Trial: 22239862
Drug: Flibanserin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 50 mg twice daily
Trial: 22239862
Drug: Flibanserin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin 25 mg twice daily
Trial: 19207432
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy using indocyanine green (ICG) dye with a diode laser
Trial: 17502777
Drug: Intramuscular biperiden
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular biperiden
Trial: 14982808
Drug: Albendazole formulations
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole formulations with arachis oil‐polysorbate 80
Trial: 14982808
Drug: Albendazole formulations
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole formulations with hydroxypropyl‐beta‐cyclodextrin
Trial: 14982808
Drug: Macrogol suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macrogol suppositories
Trial: 8633581
Drug: Sulfasalazine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (3 g/day)
Trial: 2568327
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg nizatidine nightly
Trial: 2568327
Drug: 2 X
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 X 150 mg nizatidine daily
Trial: 2568327
Drug: 2 X
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 X 150 mg ranitidine daily
Trial: 28096535
Drug: Germline SNPs
RxNorm normalized name: SNP-ACTH (1-39)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Germline SNPs associated with rapid drug clearance or drug resistance
Trial: 28096535
Drug: Asparaginase resistance
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asparaginase resistance or allergy SNPs in treatment arms
Trial: 24671237
Drug: GOS-containing infant
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOS-containing infant formula (0.44 g/dl of GOS)
Trial: 19249633
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg loading, 10 mg maintenance)
Trial: 19249633
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading, 75 mg maintenance)
Trial: 9512875
Drug: Amiloride hydrochlorothiazide
RxNorm normalized name: amiloride / hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride hydrochlorothiazide (5/50 mg/d)
Trial: 1826912
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg/d)
Trial: 9512875
Drug: Nifedipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (40 mg/d)
Trial: 18326980
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg/d)
Trial: 29718967
Drug: Bedaquiline 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedaquiline 400 mg alone
Trial: 29718967
Drug: Bedaquiline 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedaquiline 400 mg plus Rifampin 600 mg
Trial: 29718967
Drug: Bedaquiline 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedaquiline 400 mg plus Rifabutin 300 mg
Trial: 27236272
Drug: AKB‐9778 monotherapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKB‐9778 monotherapy: subcutaneous AKB‐9778 15 mg BID + monthly sham intraocular injections
Trial: 27236272
Drug: Combination therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy: subcutaneous AKB‐9778 15 mg BID + monthly 0.3 mg ranibizumab
Trial: 27236272
Drug: Ranibizumab monotherapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab monotherapy: subcutaneous placebo injections BID + monthly 0.3 mg ranibizumab
Trial: 24120712
Drug: Oseltamivir (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (75 mg b.i.d. for 5 days)
Trial: 21775146
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg/day for the first 3 days, then 300 mg/day for a further 2 days
Trial: 16546843
Drug: Doxazosin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (4 mg/day for 2 weeks)
Trial: 9878015
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination drug therapy with indinavir, zidovudine, and lamivudine
Trial: 9878015
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination drug therapy after either indinavir or zidovudine-lamivudine treatment
Trial: 9878015
Drug: Prolonged indinavir-zidovudine-lamivudine
RxNorm normalized name: lamivudine / zidovudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged indinavir-zidovudine-lamivudine treatment
Trial: 8529495
Drug: Pre-filled insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-filled insulin pen (NovoLet)
Trial: 6759062
Drug: Ciramadol 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciramadol 40 mg
Trial: 17470024
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine spray
Trial: 30920975
Drug: Silymarin 140
RxNorm normalized name: silymarin 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 140 mg/day
Trial: 27659294
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/day until disease progression or unacceptable toxicity
Trial: 25662553
Drug: Bioadhesive chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioadhesive chlorhexidine gel 0.2%
Trial: 21946712
Drug: ZeroFly® insecticide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZeroFly® insecticide incorporated plastic sheeting (deltamethrin 2.0 g/kg or 265 mg/m2)
Trial: 16754759
Drug: Team Solutions
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Team Solutions intervention (24-week psychoeducational group focused on illness management)
Trial: 11822998
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg four times daily for 10 days)
Trial: 9661546
Drug: Dexamethasone 1
RxNorm normalized name: dexamethasone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 1 mg/kg (maximal dose 25 mg)
Trial: 7631610
Drug: Noninvasive technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive technique after phenylephrine injection
Trial: 7631610
Drug: Invasive technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive technique after phenylephrine injection
Trial: 320832
Drug: Coated, rapidly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated, rapidly dissolving lithium carbonate tablets
Trial: 320832
Drug: Medium-slow-release lithium
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-slow-release lithium sulphate tablets
Trial: 320832
Drug: Slow-release lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release lithium sulphate tablets
Trial: 6182175
Drug: mianserin 10
RxNorm normalized name: mianserin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin 10 mg 3 times daily for 1 week followed by 60 mg mianserin daily for a second week
Trial: 6182175
Drug: amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amitriptyline 25 mg 3 times daily for 1 week followed by 150 mg amitriptyline daily for a second week
Trial: 6182175
Drug: placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo treatment for 14 days
Trial: 26555871
Drug: Tizanidine 4
RxNorm normalized name: tizanidine 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine 4 mg orally 1 hour before surgery and twice daily during the first postoperative week
Trial: 24826894
Drug: Prophylactic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic platelet transfusion policy (counts <10 × 10(9) /L)
Trial: 22842177
Drug: 1 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/day Fungisome
Trial: 22842177
Drug: 3 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg/day Fungisome
Trial: 22842177
Drug: 1 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/day conventional amphotericin B
Trial: 17650789
Drug: Yiguan Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yiguan Decoction (YGD) plus NP protocol of chemotherapy
Trial: 17650789
Drug: NP protocol
RxNorm normalized name: NP Thyroid Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP protocol of chemotherapy
Trial: 11844942
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment programme with hypnosis
Trial: 11844942
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment programme without hypnosis
Trial: 7444376
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of calciumacetylsalicylic acid
Trial: 7444376
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of calciumacetylsalicylic acid
Trial: 7444376
Drug: Repeated doses
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated doses of 100 mg of calciumacetylsalicylic acid at 12 h intervals
Trial: 7444376
Drug: 12 h
RxNorm normalized name: 12 Hour Cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 h 100 mg doses of calciumacetylsalicylic acid (equal to 80 mg of aspirin)
Trial: 27828791
Drug: Vernakalant (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vernakalant (3 mg/kg infusion for 10 minutes, followed by 2 mg/kg infusion for 15 minutes if needed)
Trial: 27828791
Drug: Placebo (infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (infusion for 10 minutes, followed by placebo infusion for 15 minutes if needed)
Trial: 20624152
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with docosahexaenoic acid (DHA) and arachidonic acid (AA) - 0.5 mL oil (32 mg DHA and 31 mg AA) per 100 mL milk from 1 week after birth until discharge (9 weeks on average)
Trial: 19494788
Drug: Erlotinib 1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 1400 mg weekly on days 2, 9, and 16 plus Pemetrexed 500 mg/m every 21 days (arm A)
Trial: 19494788
Drug: Erlotinib 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 250 mg on days 2 to 16 plus Pemetrexed 500 mg/m every 21 days (arm B)
Trial: 14742841
Drug: Calcium (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1.2 g/d) and vitamin D (8 microg/d) supplementation for 6 months in RYGB women with low bone mass, n = 13
Trial: 2446081
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg orally)
Trial: 2446081
Drug: Ritanserin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (10 mg orally)
Trial: 2446081
Drug: Ritanserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (20 mg orally)
Trial: 23605170
Drug: Metformin (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,500 mg) and folic acid (1 mg) per day for 2 months
Trial: 23605170
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (1 mg) per day for 2 months (Control)
Trial: 19620848
Drug: IPX054 (50/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPX054 (50/200 mg) twice daily
Trial: 19620848
Drug: CD/LD (25/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD/LD (25/100 mg) 4 times daily
Trial: 12612511
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg midazolam plus 50 mg meperidine (Group B)
Trial: 12612511
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg midazolam and placebo (Group A)
Trial: 8811136
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (Voltaren), 50 mg two or three times a day
Trial: 1329231
Drug: Teniposide administration
RxNorm normalized name: Teniposide
DrugBank: Teniposide (DB00444)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teniposide administration (schedule not specified)
Trial: 6724125
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 200 mg tablets
Trial: 6724125
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 400 mg tablets
Trial: 29618121
Drug: Strategic bDMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strategic bDMARDs treatment (ustekinumab, secukinumab, TNF inhibitors based on T cell phenotype)
Trial: 29618121
Drug: Standard bDMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bDMARDs treatment
Trial: 29521922
Drug: Foot exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot exercises (daily for 12 weeks)
Trial: 23726668
Drug: Citalopram treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram treatment for 12 weeks
Trial: 18766387
Drug: beta‐TCP (Cerasorb)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐TCP (Cerasorb) in combination with PRP
Trial: 16739362
Drug: Iberogast (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberogast (3 x 20 drops daily for 4 weeks)
Trial: 11321874
Drug: G-CSF or
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF or GM-CSF
Trial: 3444905
Drug: lonidamine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lonidamine (150 mg t.i.d.) + radiotherapy (RT)
Trial: 9016421
Drug: L-thyroxine replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine replacement therapy
Trial: 16580290
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (2 mg)
Trial: 12680890
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg x 4 for 3 days
Trial: 12680890
Drug: Paracetamol 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1000 mg x 4 for 3 days
Trial: 30158057
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of loop diuretics
Trial: 30158057
Drug: Continuous use
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous use of loop diuretics
Trial: 30158057
Drug: Initiation or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation or discontinuation of diuretics
Trial: 27647847
Drug: Renal artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal artery stenting plus optimal medical therapy
Trial: 23706520
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg daily for 20 weeks
Trial: 8305642
Drug: GFR measurements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFR measurements using renal clearance of [125I]iothalamate after an sc injection without epinephrine.
Trial: 2863920
Drug: Alprazolam (AZ)
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam (AZ) 0.25 mg
Trial: 2863920
Drug: Diazepam (DZ)
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam (DZ) 5 mg
Trial: 2863920
Drug: Alprazolam (AZ)
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam (AZ) 0.75 mg
Trial: 24802974
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral Δ(9) -tetrahydrocannabinol (THC)
Trial: 20689095
Drug: Pro-CHO (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro-CHO (3.6 kcal/kg, 0.36 g protein/kg)
Trial: 18573825
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta therapy
Trial: 12809076
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (200 mg intramuscularly every 2 weeks)
Trial: 8758538
Drug: Alpha Interferon
RxNorm normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha Interferon therapy
Trial: 8758538
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus natural alpha Interferon